- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05491252
A Randomized Controlled Trial of Patient-Centered Self-Management Intervention in Adults With Type 2 Diabetes Mellitus
A Patient-Centered Self-Management Intervention to Improve Glycemic Control, Self-Efficacy and Self-Care Behaviors in Adults With Type 2 Diabetes Mellitus: Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: In Pakistan, the rising burden of type 2 Diabetes Mellitus (DM) and its associated complications is considerably affecting the functional capacity of the individuals, their quality of life and demand for healthcare services with significant economic impact on health care system and the national economy. Given its enormous health and economic impact, preventing type 2 DM progression and reducing the risk of associated complications requires immediate attention. Evidence suggests that self-management can slow the progression of type 2 DM and minimize the risk of major complications thereby lowering health-care costs. Efective self-management on the other hand, demands patients' confidence and their full commitment to perform self care tasks necessitating a patient-centered approach.
Objective: To test the efficacy of a patient centered self-management intervention to improve glycemic control, self-efficacy and self-care behaviors in adults with type 2 DM.
Setting, Duration, Study Type: The study will be carried out as a randomized controlled trial (RCT) in four public tertiary care hospitals in Faisalabad, Pakistan.
Methods: A total 612 subjects will be recruited from out-patient departments (OPDs) of the study hospitals. Using random allocation 306 subjects will be assigned to the control group and 306 to the intervention group. Both the control group and the intervention group will receive usual care delivered at study hospitals. The intervention group will additionally receive a patient centered self-management Intervention for eight weeks duration.
Expected Outcome: If the study is able to show that the intervention group had improved glycemic control, self-efficacy and self-care behaviors than the control group. Then, employing hospital policies, this evidence-based care may be provided to all DM patients.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Punjab
-
Faisalabad, Punjab, Pakistan, 38000
- District Head Quarter (DHQ) Hospital
-
Faisalābad, Punjab, Pakistan, 38000
- Allied Hospital
-
Faisalābad, Punjab, Pakistan, 38000
- Government General Hospital
-
Faisalābad, Punjab, Pakistan, 38000
- Punjab Social Security Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult (aged 18 years or above)
- Diagnosed with type 2 Diabetes Mellitus for at least 06 months duration.
- Willing to participate in the study by signing of the consent form.
Exclusion Criteria:
- Type 2 DM Patient with HbA1c < 7
- Uncontrolled psychological comorbidity (psychosis, schizophrenia, dementia or severe learning difficulties).
- Severe comorbidity that may limit participation (medical conditions such as cancer, stroke with disabilities, or need for regular dialysis etc. that preclude complete participation in this study).
- Life expectancy of less than six months as determined by patient's primary physician.
- Living outside of Faisalabad City.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control Group (CG)
The subjects in the Control Group (CG) will receive usual care as being received in study hospitals.
Usual care at study hospitals involve consultaion with the physician which encompasses history taking, blood glucose measurement, prescription and provision of general education regarding lifestyle modification verbally or in the form of pamphelets.
|
|
Experimental: Intervention Group (IG)
The subjects in the Intervention Group (IG) will receive usual care as well as a nurse-led PAtient CEntered Self-Management Intervention (PACE-SMI).
PACE-SMI will be delivered for eight weeks duration comprising eight face to face individual and group educational, couselling and behavioral (ECB) training sessions in addition to telephonic reminders and a home visit by Principal Investigator (PI) and Research Assistants (RA).
Outcome variables will be measured at three points in time (at baseline, at completion of intervention and lastly, after three months follow-up).
|
Week 1: General disease knowledge. Week 2: Role of self-care behaviors towards effective management of type 2 diabetes, motivational video and real story of a diabetic patient to serve as a role-model. Lastly, provision of diabetes self-care guidebook. Week 3: Home visit to observe facilitators and barriers on initiating and maintaining behavioral change with social support as a key strategy. Week 4: ECB session on Diet. Week 5: ECB session on Physical Activity. Week 6: ECB session on Foot Care. Week 7: ECB session on Medication Adherence. Week 8: Booster session comprising reflection, performance feedback and review of behavioral goals fostering continued performance accomplishment and addressing difficulties of maintaining behaviour change over time. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Glycemic Control (HbA1c)
Time Frame: HbA1c will be measured at three points in time (1) at baseline, (2) at completion of 8 weeks intervention, and (3) at three months follow-up
|
HbA1c will be measured by collecting venous plasma samples and sending them to the single central laboratory to assure consistency and uniformity in methodology.
The samples will be drawn by Data Collectors/Outcome Assessors and laboratory measurements will be performed by a trained laboratory technician.
|
HbA1c will be measured at three points in time (1) at baseline, (2) at completion of 8 weeks intervention, and (3) at three months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self Efficacy
Time Frame: Self Efficacy will be measured at three points in time (1) at baseline, (2) at completion of 8 weeks intervention, and (3) at three months follow-up
|
Self Efficacy will be measured on Diabetes management self-efficacy scale (DMSES).
DMSES is a self-administered scale used to assess subjects's perceived confidence in their ability to manage blood sugar, diet, physical activity and foot care.
The scale comprises of 20 items.
Each item's response is rated on 11 point scale ranging from 'cant do at all (0)' to 'certain can do it' (10) with total score 0 to 200.
|
Self Efficacy will be measured at three points in time (1) at baseline, (2) at completion of 8 weeks intervention, and (3) at three months follow-up
|
Self Care Behaviors
Time Frame: Self care behaviors will be measured at three points in time (1) at baseline, (2) at completion of 8 weeks intervention, and (3) at three months follow-up
|
Self Care Behaviors will be measured on Summary of diabetes self-care activities (SDSCA).
SDSCA is a self-reported scale to measure self-care activities across diverse components of diabetes self-management.
SDSCA comprises of 25 items with each item measuring the frequency of self-care activities by asking how often several self-care activities were carried out over past seven days period.
Each item's response is rated on 7 point scale ranging from '0' to '7' with total score ranging from 0 to 175.
A higher score would be the frequency of performing self-care activities.
|
Self care behaviors will be measured at three points in time (1) at baseline, (2) at completion of 8 weeks intervention, and (3) at three months follow-up
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Khairunnisa Dhamani, PhD, Shifa Tameer e Millat University, Islamabad, Pakistan
- Study Director: Erika Froelicher, PhD, Shifa Tameer-e-Millat University
- Study Director: Raisa Gul, PhD, Shifa Tameer-e-Millat University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 335-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on PAtient CEntered Self-Management Intervention (PACE-SMI)
-
Barts & The London NHS TrustAsthma UK; Social Action for Health; Department of Health (Service Support); Noreen...Completed
-
Dartmouth-Hitchcock Medical CenterNational Institute of Mental Health (NIMH)CompletedDepression | Schizophrenia | Schizoaffective Disorder | Bipolar DisorderUnited States
-
Uskudar UniversityHacettepe UniversityCompletedDiabetes Mellitus, Type 2 | Occupational TherapyTurkey
-
Zhejiang UniversityRecruitingBrain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Cognitive Impairment | Alzheimer Disease | Mental Disorder | Cognition Disorder | Vascular Cognitive Impairment | DementChina
-
University of South CarolinaNational Institute on Aging (NIA)Recruiting
-
University of PennsylvaniaCompletedGeneral Medical Inpatient ConditionsUnited States
-
Sint MaartenskliniekRadboud University Medical CenterCompletedMusculoskeletal Diseases | Rheumatoid ArthritisNetherlands
-
Northwestern UniversityNational Cancer Institute (NCI); Northwestern MedicineActive, not recruiting
-
Agency for Healthcare Research and Quality (AHRQ)National Institute of Mental Health (NIMH); Aetna, Inc.Unknown
-
Assistance Publique - Hôpitaux de ParisCompletedRheumatoid Arthritis (RA) | Spondyloarthritis (SpA)France